Increasing incidences of cardiovascular diseases is primarily driving the cardiovascular drugs market size during the forecast time line. Furthermore, rising number of obese and diabetes patients is positively affecting the industry growth rate. Unhealthy lifestyle accompanied with poor eating habits is supporting in revenue generation of the industry.
The global cardiovascular drugs market is expected to be around US$ 93.20 Bn by 2028 CAGR of over 1.0% from 2023 to 2028.
Drug discovery and drug development programs for various applications will further enhance the demand for cardiovascular drugs market. Recent developments in cardiovascular drugs including Esperion Therapeutics’ novel LDL-lowering drug ETC-1002, Pfizer’s PCSK9 inhibitor, and Merck’s CETP inhibitor anacetrapib will further escalate the industry size over the forecast time span.
Global cardiovascular drugs market is segmented based on the drug class as, Renin-Angiotensin System Blockers, Beta Blockers, Diuretics, Anti-Clotting, Antihyperlipidemics, Calcium Channel Blockers and others. On the basis of indication, the global cardiovascular drugs market is segregated as Hypertension, Hyperlipidemia, Coronary Artery Disease, Peripheral Artery Disease, Arrhythmia, and others. Hypertension is expected to witness notable gains in the forecast years. The report segments global cardiovascular drugs market based on distribution channel as Hospital, Retail, and Online.
Global cardiovascular drugs market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional cardiovascular drugs market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global cardiovascular drugs market share consists of several players including AstraZeneca plc, Johnson & Johnson, Merck & Co., Sanofi S.A., Roche Holding AG, Novartis AG, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Pfizer, Inc., and Bayer AG.
The Cardiovascular Drugs Market has been segmented as below:
Cardiovascular Drugs Market, By Drug Class
Cardiovascular Drugs Market, By Indications
Cardiovascular Drugs Market, By Distribution Channel
Cardiovascular Drugs Market, By Region
The report covers:
Report scope:
The global cardiovascular drugs market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends. The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AstraZeneca plc, Johnson & Johnson, Merck & Co., Sanofi S.A., Roche Holding AG, Novartis AG, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Pfizer, Inc., and Bayer AG.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising incidences cardiovascular disease
4.2.2. Increasing number of diabetes and obese patients
4.3. Restraints
4.3.1. Patent expiry of various popular drugs
4.3.2. Stringent regulations
4.4. Opportunities
4.4.1. Rising merger and acquisitions
4.4.2. Increased awareness about heart diseases
4.5. Challenges
4.5.1. Side-effects of cardiovascular drugs
5. Cardiovascular Drugs Market, By Drug Class
5.1. Key Points
5.2. Renin-Angiotensin System Blockers
5.2.1. ACE Inhibitors
5.2.2. Angiotensin Receptor Blockers
5.3. Beta Blockers
5.4. Diuretics
5.5. Anti-Clotting Agents
5.5.1. Anti-Coagulants
5.5.2. Platelet Aggregation Inhibitors
5.6. Antihyperlipidemics
5.7. Calcium Channel Blockers
5.8. Others
6. Cardiovascular Drugs Market, By Indications
6.1. Key Points
6.2. Hypertension
6.3. Hyperlipidemia
6.4. Coronary Artery Disease
6.5. Peripheral Artery Disease
6.6. Arrhythmia
6.7. Others
7. Cardiovascular Drugs Market, By Distribution Channel
7.1. Key Points
7.2. Hospital
7.3. Retail
7.4. Online
8. Competitive Landscape
8.1. Introduction
8.2. Recent Developments
8.2.1. Mergers & Acquisitions
8.2.2. New Product Developments
8.2.3. Portfolio/Production Capacity Expansions
8.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
8.2.5. Others
9. Company Profile
9.1. AstraZeneca plc
9.1.1. Company Overview
9.1.2. Product/Service Landscape
9.1.3. Financial Overview
9.1.4. Recent Developments
9.2. Johnson & Johnson
9.2.1. Company Overview
9.2.2. Product/Service Landscape
9.2.3. Financial Overview
9.2.4. Recent Developments
9.3. Merck & Co.
9.3.1. Company Overview
9.3.2. Product/Service Landscape
9.3.3. Financial Overview
9.3.4. Recent Developments
9.4. Sanofi S.A.
9.4.1. Company Overview
9.4.2. Product/Service Landscape
9.4.3. Financial Overview
9.4.4. Recent Developments
9.5. Roche Holding AG
9.5.1. Company Overview
9.5.2. Product/Service Landscape
9.5.3. Financial Overview
9.5.4. Recent Developments
9.6. Novartis AG
9.6.1. Company Overview
9.6.2. Product/Service Landscape
9.6.3. Financial Overview
9.6.4. Recent Developments
9.7. Takeda Pharmaceutical Company Limited
9.7.1. Company Overview
9.7.2. Product/Service Landscape
9.7.3. Financial Overview
9.7.4. Recent Developments
9.8. Daiichi Sankyo Company Limited
9.8.1. Company Overview
9.8.2. Product/Service Landscape
9.8.3. Financial Overview
9.8.4. Recent Developments
9.9. Pfizer, Inc.
9.9.1. Company Overview
9.9.2. Product/Service Landscape
9.9.3. Financial Overview
9.9.4. Recent Developments
9.10. Bayer AG.
9.10.1. Company Overview
9.10.2. Product/Service Landscape
9.10.3. Financial Overview
9.10.4. Recent Developments
The Cardiovascular Drugs Market has been segmented as below:
Cardiovascular Drugs Market, By Drug Class
Cardiovascular Drugs Market, By Indications
Cardiovascular Drugs Market, By Distribution Channel
Cardiovascular Drugs Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
